Gender Dysphoria: Epidemiological Data (DyGenEpi)

September 28, 2020 updated by: Central Hospital, Nancy, France

Epidemiological Characteristics of the Population of Persons With Gender Dysphoria : Data From the Cohort Follow-up in CHRU de Nancy

Retrospective study in a single academic regional transgender referral center. data from the cohort follow-up in CHRU de Nancy

Study Overview

Status

Unknown

Conditions

Gender Dysphoria

Intervention / Treatment

Other: descriptive study

Study Type

Observational

Enrollment (Anticipated)

320

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

France
- - Nancy, France, 54000
    - CHRU Nancy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child
Adult
Older Adult

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Subjects who met diagnostic criteria for gender dysphoria (International Classification of Diseases 11th Revision. https://icdwhoint. 2018) and were seen regularly in the outpatient clinic at our department of endocrinology

Description

Retrospective analysis of available data as a part of the regular care of subjects with gender dysphoria. All measurements were made at the time of the routine follow-up visits

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Models: Cohort
Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incdience rate of cardiovascular diseases Time Frame: 2004-2020	Number of new cases of arterial hypertension, stroke, myocardial infarction during the specified period (2004-2020) /Time each person was observed, totaled for all persons	2004-2020
Incidence rate of dyslipidemia Time Frame: 2004-2020	Number of new cases of dyslipidemia during the specified period (2004-2020) /Time each person was observed, totaled for all persons	2004-2020

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence rate of oncological diseases Time Frame: 2004-2020	Number of new cases of malignancies during the specified period (2004-2020) /Time each person was observed, totaled for all persons	2004-2020
Incidence rate of psychiatric diseases Time Frame: 2004-2020	Number of new cases of psychiatric diseases malignancies during the specified period (2004-2020) /Time each person was observed, totaled for all persons	2004-2020
Overall mortality rate Time Frame: 2004-2020	Mortality during the specified period (2004-2020) /Time each person was observed, totaled for all persons	2004-2020

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central Hospital, Nancy, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 27, 2020

Primary Completion (Anticipated)

November 1, 2021

Study Completion (Anticipated)

November 1, 2021

Study Registration Dates

First Submitted

August 7, 2020

First Submitted That Met QC Criteria

September 28, 2020

First Posted (Actual)

October 5, 2020

Study Record Updates

Last Update Posted (Actual)